Skip to main content

Atossa Therapeutics, Inc.

ATOS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001488039

No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Atossa Therapeutics, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of ATOS: Q1 2026 compared with Q2 2026
MeasureQ1 2026Q2 2026Change
Holders3331−2
Shares1.24M1.35M+105.3K (+8.5%)
Value$6.52M$2.60M−$3.92M (−60.2%)

New holders (5)

Institutions that held Atossa Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to ATOS in Q2 2026
InstitutionSharesValue% of portfolio
Jane Street Group, LLC56,602$109.2K0.00%
Susquehanna International Group, LLP15,574$30.1K0.00%
MCF Advisors LLC1,066$2.06K0.00%
Caitong International Asset Management Co., Ltd6$120.00%
Bessemer Group Inc6$00.00%

Sold out (7)

Institutions that held Atossa Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of ATOS in Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
Tower Research Capital LLC (TRC)863$4.54K
GWM Advisors LLC333$1.75K
Avion Wealth318$1.00K
Robinswood Financial LLC170$894
North Star Investment Management Corp.80$421
Northwestern Mutual Wealth Management Co46$242
Allworth Financial LP46$242